5th Glioblastoma Drug Development Summit

March 26 - 28, 2024 - MA US

Hanson Wade

info@hansonwade.com
Phone:+1 617 455 4188

The 5th Glioblastoma Drug Development Summit is the only industry led forum for large pharma, biotech, neuro-oncologists and academic KOLs to unite alongside a dedicated panel of investors under the common goal to breakthrough GBM barriers to accelerate the practical translation and clinical development of emerging therapeutics for glioblastoma and CNS tumor patients. Discover innovative approaches to surpassing the blood-brain barrier to unlock previously uncovered therapeutic potential, keep ahead of the latest clinical trial design rationale and navigate the regulatory landscape for novel combination therapies with actionable insights to improve clinical success. With promising clinical readouts from a range of therapeutic modalities, novel drug targets emerging and positive advances in state-of-the-art technologies like sonodynamic therapy, there is more potential than ever before to be unlocked within the GBM space. To elevate your current standards, join this unique collaboration between industry giants such as Novartis, pioneering biotechs such as Day One Biopharmaceuticals, world-renowned academics and investors. Embrace positive clinical outcomes alongside a dedicated community committed to defeating GBM/CNS tumors and transforming lives. Access the complete agenda here including a packed pre-workshop conference day, panel discussions, poster sessions and important networking opportunities. Visit www.glioblastoma-drugdevelopment.com for full details. Time: 8:30 AM - 5:30 PM

More Information